APA (7th ed.) Citation

H, H., SJ, B., E, A., S, A., J, L., J, Y., . . . MWL, T. (2018). Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis. Oncoimmunology, 7(7), e1445949. https://doi.org/10.1080/2162402X.2018.1445949

Chicago Style (17th ed.) Citation

H, Harjunpää, et al. "Deficiency of Host CD96 and PD-1 or TIGIT Enhances Tumor Immunity Without Significantly Compromising Immune Homeostasis." Oncoimmunology 7, no. 7 (2018): e1445949. https://doi.org/10.1080/2162402X.2018.1445949.

MLA (9th ed.) Citation

H, Harjunpää, et al. "Deficiency of Host CD96 and PD-1 or TIGIT Enhances Tumor Immunity Without Significantly Compromising Immune Homeostasis." Oncoimmunology, vol. 7, no. 7, 2018, p. e1445949, https://doi.org/10.1080/2162402X.2018.1445949.